Protection from pathological tau by activation of the ER unfolded protein response
Protection from pathological tau by activation of the ER unfolded protein response
批准号:
10347310
负责人:
Brian C. Kraemer
金额:
$52.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-02-01 至 2025-01-31
关键词:
ATF6 geneAddressAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease related dementiaAnimal ModelAnimalsBioinformaticsBrainCaenorhabditis elegansCellular StressCessation of lifeDementiaDepositionDiagnosticDiseaseDisease modelEndoplasmic ReticulumExhibitsFrontotemporal Lobar DegenerationsFunctional disorderFutureGenesGenetic TranscriptionGoalsHumanLaboratoriesLesionMammalsMediatingModelingMolecularMolecular GeneticsMolecular TargetNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesNeuronal DysfunctionNeuronsPathologicPathologyPatientsPhenotypeProgressive Supranuclear PalsyProtein IsoformsProteinsRoleSystemTauopathiesTestingToxic effectTransgenesTransgenic ModelTransgenic OrganismsWorkXBP1 genebrain tissueeffective therapyendoplasmic reticulum stressgenome wide association studyhuman diseasehyperphosphorylated taumisfolded proteinmouse modelneuroprotectionneurotoxicityprematureresponseresponse biomarkertau Proteinstau aggregationtau mutationtranscriptomicstranslational potentialtranslational study
中文摘要
神经元中异常聚集的tau蛋白的病理性沉积是诊断的方法之一
阿尔茨海默病(AD)和相关痴呆(ADRD)的标志。病理性tau蛋白如何导致
神经元的功能障碍和退化仍然是一个谜。然而,神经元功能障碍和
神经退化显然会导致痴呆为了了解异常的tau蛋白如何影响
在AD和ADRD的神经退行性变中,我们建立了C.优雅的,
由人类tau聚集驱动的神经变性。在我们以前的工作中,我们确定了XBP-1,
未折叠蛋白反应(UPR)的主要转录调节因子,作为
病理性tau积聚和毒性。ER应激和UPR的激活已经清楚地
在人类tau蛋白病疾病的其他实验室,虽然功能性后果
UPR激活对tau病理学的影响尚不清楚。我们利用了我们的C。elegans模型
tau蛋白病的研究,以剖析UPR在tau蛋白病中的功能作用。我们发现tau蛋白病理学
可诱导ER应激,UPR激活可通过XBP-1保护tau蛋白病。我们
假设XBP-1 s靶向基因可以调节病理性tau积累和清除。
为了验证这一假设,我们在没有ER应激的情况下上调了神经元中的UPR,使用了一种新的方法。
表达转基因的组成型活性XBP-1。该系统的转录组学研究
揭示了XBP-1 s调节tau蛋白病的关键靶基因,并与其他调节因子发生交叉作用。
普遍定期审议的分支(ATF 6和PERK分支)。鉴于普遍定期审议的高度保守性,
哺乳动物与C.我们建议利用现有的模型和转基因,
剖析UPR保护tau神经毒性的机制。的具体目标
本研究的主要目的是:1)确定XBP 1 s介导的抑制细胞凋亡的分子机制。
tau蛋白病; 2)检查有助于tau蛋白清除和ER相关的UPR分支串扰
3)解决XBP-1 s靶基因与神经变性的疾病相关性,
人类疾病和tau蛋白病的小鼠模型。如按建议完成项目,
告知UPR参与tau蛋白病的分子机制。我们还将探索
XBP-1 s介导的哺乳动物脑中tau蛋白清除的神经保护翻译潜力。
英文摘要
Pathological deposition of abnormal aggregated tau protein in neurons is one of the diagnostic
hallmarks of Alzheimer's disease (AD) and related dementia (ADRD). How pathological tau causes
dysfunction and degeneration of neurons remains an enigma. However, neuronal dysfunction and
neurodegeneration clearly cause dementia. To understand how abnormal tau contributes to
neurodegeneration in AD and ADRD, we established a transgenic model in C. elegans for
neurodegeneration driven by human tau aggregation. In our previous work, we identified XBP-1, the
master transcriptional regulator of the unfolded protein response (UPR), as a critical regulator of
pathological tau accumulation and toxicity. ER stress and activation of the UPR have clearly been
implicated in human tauopathy disorders by other laboratories although the functional consequences
of UPR activation on tau pathology remain unclear. We have leveraged our C. elegans model of
tauopathy to dissect the functional role of the UPR in tau pathology. We have found that tau pathology
can induce ER stress, and that UPR activation protects against tauopathy through XBP-1s. We
hypothesize that XBP-1s target genes can modulate accumulation and clearance of pathological tau.
To test this hypothesis, we upregulated the UPR in neurons in the absence of ER stress, using a
constitutively active XBP-1s expressing transgene. Transcriptomic studies of this system have
revealed key XBP-1s target genes that modulate tauopathy and cross talk with other regulatory
branches of the UPR (ATF6 and PERK branches). Given the high level of conservation of the UPR
system between mammals and C. elegans, we propose to utilize the existing model and transgenes to
dissect the mechanism by which the UPR protects against tau neurotoxicity. The Specific Aims of
this project are to: 1) Identify the molecular mechanisms of XBP1s mediated suppression of
tauopathy; 2) Examine UPR branch crosstalk contributing to tau clearance and ER associated
degradation, 3) Address the disease relevance of XBP-1s target genes to neurodegeneration in
both human disease and mouse models of tauopathy. Completion of the project as proposed will
inform the molecular mechanisms by which the UPR participates in tauopathy. We will also explore
the neuroprotective translational potential of XBP-1s mediated tau clearance in the mammalian brain.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SPOP drives neurodegenerative tauopathy
-
批准号:10734807
-
项目类别:
-
资助金额:$182.34万
-
财政年份:2023
-
负责人:Brian C. Kraemer
-
依托单位:
Targeting MSUT2 with small molecules to ameliorate pathological tau
-
批准号:10735826
-
项目类别:
-
资助金额:$218.13万
-
财政年份:2023
-
负责人:Brian C. Kraemer
-
依托单位:
Formation of Tau RNA Complexes disrupts tau function and drives tau neuropathology
-
批准号:10777174
-
项目类别:
-
资助金额:$63.88万
-
财政年份:2023
-
负责人:Brian C. Kraemer
-
依托单位:
Developing MSUT2 Nanobodies for Targeting Pathological Tau in Alzheimer's Disease
-
批准号:10518408
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:Brian C. Kraemer
-
依托单位:
Developing MSUT2 Nanobodies for Targeting Pathological Tau in Alzheimer's Disease
-
批准号:10363866
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:Brian C. Kraemer
-
依托单位:
Reversal of Tau Pathology with MSUT2 siRNA Conjugates
-
批准号:10240452
-
项目类别:
-
资助金额:$9.99万
-
财政年份:2020
-
负责人:Brian C. Kraemer
-
依托单位:
Reversal of Tau Pathology with MSUT2 siRNA Conjugates
-
批准号:9909831
-
项目类别:
-
资助金额:$21.3万
-
财政年份:2020
-
负责人:Brian C. Kraemer
-
依托单位:
Protection from pathological tau by activation of the ER unfolded protein response
-
批准号:10551219
-
项目类别:
-
资助金额:$52.0万
-
财政年份:2020
-
负责人:Brian C. Kraemer
-
依托单位:
Protection from pathological tau by activation of the ER unfolded protein response
-
批准号:9901055
-
项目类别:
-
资助金额:$53.0万
-
财政年份:2020
-
负责人:Brian C. Kraemer
-
依托单位:
Inhibiting pathological TDP-43 phosphorylation as a therapeutic strategy for ALS
-
批准号:9348132
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Brian C. Kraemer
-
依托单位:
Inhibiting pathological TDP-43 phosphorylation as a therapeutic strategy for ALS
-
批准号:9898277
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:Brian C. Kraemer
-
依托单位:
MSUT2 modulates pathological tau in AD and model organisms
-
批准号:9285130
-
项目类别:
-
资助金额:$317.4万
-
财政年份:2017
-
负责人:Brian C. Kraemer
-
依托单位:
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease
-
批准号:10624460
-
项目类别:
-
资助金额:$78.66万
-
财政年份:2016
-
负责人:Brian C. Kraemer
-
依托单位:
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease
-
批准号:10410126
-
项目类别:
-
资助金额:$76.58万
-
财政年份:2016
-
负责人:Brian C. Kraemer
-
依托单位:
Acquisition of a ProteinSimple capillary electrophoresis protein immunoanalyzer
-
批准号:8949379
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Brian C. Kraemer
-
依托单位:
Unfolded protein response activation protects neurons against pathological tau
-
批准号:9064862
-
项目类别:
-
资助金额:$17.58万
-
财政年份:2015
-
负责人:Brian C. Kraemer
-
依托单位:
Identifying new tau targeted therapeutics: a drug repurposing approach
-
批准号:9275429
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Brian C. Kraemer
-
依托单位:
Identifying new tau targeted therapeutics: a drug repurposing approach
-
批准号:8994167
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Brian C. Kraemer
-
依托单位:
Identifying new tau targeted therapeutics: a drug repurposing approach
-
批准号:8815851
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Brian C. Kraemer
-
依托单位:
MSUT2/SUT2 controls tau protein aggregation and neurotoxicity.
-
批准号:8198359
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Brian C. Kraemer
-
依托单位:
海外基金